Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (University of Minnesota)
- Development stage
- Unknown
- Lead developer
- University of Minnesota
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplant is a live biotherapeutic product being investigated by the University of Minnesota for the treatment of hidradenitis suppurativa (HS). [18] It is formulated as lyophilized (freeze-dried) powder in oral capsules. [12, 13] The therapy is based on the hypothesis that altering the patient's gut microbiome can influence the cutaneous (skin) microbiome and reduce systemic inflammation through gut-derived metabolites, thereby improving the symptoms of HS. [12, 14, 16] A pilot study is underway to evaluate the safety and efficacy of this approach. [12]
- Other names
- Microbiota Transplant TherapyMTTfecal microbiota - lyophilizedfecal microbiota-University of Minnesota-hidradenitis suppurativa
Beyond the preview
Go deeper on fecal microbiota transplant (University of Minnesota).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (University of Minnesota).